Quick Answer
KESTRA MEDICAL TECHNOLOGIES, LTD. reported Total Revenue of $59.81 million for fiscal year 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $59.81M +115.1% |
$27.81M | — |
| Revenue (ASC 606) | $59.81M +115.1% |
$27.81M | — |
| Net Income | -$113.81M -20.9% |
-$94.12M | — |
| Diluted EPS | -$5.13 -1.2% |
-$5.07 | — |
| Total Assets | $295.74M +543.6% |
$45.95M | — |
| Cash and Equivalents | $237.59M +2780.3% |
$8.25M | — |
| Long-Term Debt | $41.10M -3.4% |
$42.54M | — |
| Stockholders Equity | $205.41M +198.1% |
-$209.38M -78.1% |
-$117.58M |
| R&D Expense | $15.65M +1.0% |
$15.49M | — |
| Operating Income | -$106.38M -25.1% |
-$85.06M | — |
| Gross Profit | $24.21M +6587.8% |
$362.0K | — |
| Shares Outstanding | 51.35M +48430.0% |
105,808 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $24.55M | +62.7% | +8.8% |
| Revenue (ASC 606) | January 31, 2026 | $24.55M | +62.7% | +8.8% |
| Net Income | January 31, 2026 | -$34.17M | -58.8% | -4.2% |
| Diluted EPS | January 31, 2026 | -$0.61 | +51.2% | +4.7% |
| Total Assets | January 31, 2026 | $379.34M | — | +53.8% |
| Cash and Equivalents | January 31, 2026 | $291.32M | +436.0% | +66.1% |
| Long-Term Debt | January 31, 2026 | $42.26M | — | +0.9% |
| Stockholders Equity | January 31, 2026 | $287.99M | +211.7% | +75.5% |
| R&D Expense | January 31, 2026 | $4.97M | +48.3% | +1.9% |
| Operating Income | January 31, 2026 | -$34.77M | -68.8% | -9.5% |
| Gross Profit | January 31, 2026 | $12.91M | +97.1% | +13.0% |
| Shares Outstanding | January 31, 2026 | 58.35M | +58348953.0% | +13.4% |
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Total Revenue of $59.81 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +115.1% in Total Revenue compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Revenue (ASC 606) of $59.81 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +115.1% in Revenue (ASC 606) compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Net Income of -$113.81 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed a decrease of -20.9% in Net Income compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Diluted EPS of $5.13 per share (loss) for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed a decrease of -1.2% in Diluted EPS compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Total Assets of $295.74 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +543.6% in Total Assets compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Cash and Equivalents of $237.59 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +2780.3% in Cash and Equivalents compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Long-Term Debt of $41.10 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed a decrease of -3.4% in Long-Term Debt compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Stockholders Equity of $205.41 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +198.1% in Stockholders Equity compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported R&D Expense of $15.65 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +1.0% in R&D Expense compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Operating Income of -$106.38 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed a decrease of -25.1% in Operating Income compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Gross Profit of $24.21 million for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +6587.8% in Gross Profit compared to the prior fiscal year.
- KESTRA MEDICAL TECHNOLOGIES, LTD. reported Shares Outstanding of 51.35 million shares for fiscal year 2025.
- KESTRA MEDICAL TECHNOLOGIES, LTD. showed an increase of +48430.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: